China urges local firms not to use Nvidia's H20 chips, Bloomberg News reports
Several companies were sent official notices discouraging the use of the H20, a less-advanced chip, mainly for any government or national security-related work by state enterprises or private companies, the report said, citing people familiar with the matter.
Reuters could not immediately confirm the report.
Nvidia said on Tuesday the H20 chip was "not a military product or for government infrastructure".
"China has ample supply of domestic chips to meet its needs. It won't and never has relied on American chips for government operations, just like the U.S. government would not rely on chips from China," the statement said.
Washington last month lifted a ban on the sale of the H20 chip in China and it is now the most advanced artificial intelligence chip that Nvidia is allowed to sell there.
The move comes after reports in China's state media of security concerns around H20 chips. Nvidia has said there are no "backdoors" that would allow remote access or control.
Beijing is pressuring China's large tech firms such as Alibaba and ByteDance over orders of H20 chips, the Financial Times reported on Tuesday.
The companies have been asked by the Ministry of Industry and Information Technology to explain why they need to order H20 chips instead of using domestic alternatives, the report said, citing people familiar with the matter.
Some tech companies were planning to reduce their orders as a result of the questions from regulators, the report said.
The Information reported the companies along with Tencent Holdings, have been ordered by China's internet regulator in the past two weeks to suspend their purchases of Nvidia chips altogether, citing data security concerns with the chips.
The directive came from the Cyberspace Administration of China and was communicated at a meeting the regulator convened with over a dozen Chinese tech firms, shortly after the Trump administration reversed the export curbs on H20 chips, according to the report.
The regulator told the companies that new chip purchases had to be suspended until it concluded an investigation into potential security risks from the chips, according to the report, which cited people familiar with the matter.
Alibaba, ByteDance and Tencent did not immediately respond to Reuters requests for comments.
Nvidia did not immediately respond to a request for comment on The Information's and the Financial Times' reports.
China is also trying to promote the use of domestically-developed technologies including AI chips made by Huawei, the Chinese rival with which Nvidia is battling for AI chip dominance.
Shares in China's top contract chipmaker SMIC rose 5% on Tuesday on expectations of rising demand for locally-produced chips.
The H20 curb also follows comments on Monday from U.S. President Donald Trump, suggesting that he might allow Nvidia to sell a scaled-down version of its advanced Blackwell chip in China, despite deep-seated fears in Washington that Beijing could harness U.S. AI capabilities to supercharge its military.
China's foreign ministry said on Tuesday it hoped the U.S. would take practical action to maintain the stability and smooth operation of the global chip supply chain.
The Trump administration last week confirmed an unprecedented deal with Nvidia and AMD to give the U.S. government 15% of revenue from sales of some advanced chips in China.
China's renewed guidance on avoiding chips also affects AI accelerators from Advanced Micro Devices, the Bloomberg report said, adding that it was unclear whether any notices from Chinese authorities specifically mentioned AMD's MI308 chip.
AMD did not respond to a request for comment outside regular business hours.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Alcon Underscores Benefits of Its IOLs and Cataract Surgical Equipment at APACRS
Data on Alcon's products across cataract, refractive, diagnostics and ocular health will be featured in presentations during the meeting Prospective analyses and studies demonstrate sustained performance of Vivity including in patients with common mild comorbidities Alcon's Symposia on new generation phaco and vitrectomy system will discuss new data on anterior chamber stability during cataract surgery performed at more physiologic IOP AHMEDABAD, India, August 19, 2025--(BUSINESS WIRE)--Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced a strong presence at the 37th Asia-Pacific Association of Cataract and Refractive Surgeons (APACRS) Annual Meeting. APACRS will be held at Mahatma Mandir Convention and Exhibition Centre (MMCEC) in Ahmedabad, India from August 21-23, 2025. The company will showcase four symposia, lead 10 medical affairs scientific exchange presentations, and offer a hands-on experience zone at booth #A1). These comprehensive activities combined with new data underscore Alcon's commitment to generating meaningful scientific evidence on the safety and efficacy of its innovations. Massimo Cerrone, Vice President, Surgical for Alcon Asia Pacific, said, "APACRS brings together leading experts and their insights from across the region, creating an ideal environment to engage in critical topics such as the evolving needs of cataract care in the ageing population. Through a dynamic agenda, surgeons can explore Alcon's latest innovations and their value through clinical evidence, real-world insights, and peer experience across Asia-Pacific." Key data being presented at this year's event Alcon's Vivity® is an extensively studied Extended Depth of Focus (EDOF) intraocular lens (IOL) in special populations with different co-morbidities, supported by over 10 clinical studies involving more than 700 patients. Among these is a prospective study titled, 'To Evaluate The Visual Outcomes and Patient Satisfaction After Bilateral Vivity® IOL Implantation in Patients with Mild Irregular Astigmatism.' Conducted by Dr. Ashvin Agarwal, analyses reinforce patient satisfaction outcomes with Vivity in this specific cohort. This will be shared as an e-poster. On the cataract equipment side, Dr. Shail Vasavada of Raghudeep Eye Hospital, will present a prospective, randomized, single masked, single-center study titled, 'Retinal Perfusion During Cataract Surgery With Varying Intraocular Pressure in Comorbid Eyes.' Data underlines the benefits of performing cataract surgery at more physiologic IOP in patients with diabetic retinopathy. (Friday, 22 August 2025, 15:20pm-15:25pm, at FP3-15, Seminar Hall 2, MMCEC) Amar Vyas, Country Head, Alcon India said, "We are excited that India is hosting APACRS for the second time. The event is an ideal platform to showcase our breakthrough technologies like the Advanced Technology IOL portfolio and UNITY VCS/CS, and foster meaningful exchange amongst ECPs. As cataract procedures rise, it's critical that advanced technologies are both clinically proven across diverse patient populations and accessible to those who need them. We remain committed to empowering surgeons with science-backed solutions that elevate surgical precision and patient outcomes." During the meeting, Alcon will host four symposia; interested participants can learn more and register at Alcon UNITY® VCS Launch Symposium - Ready to explore the future of Surgical Innovation? Experience Superior Efficiency - Unity® VCS, held exclusively for India on Thursday, 21 August 2025, 12:45pm to 13:40pm IST at Seminar Hall 2, Ground Floor. This session will mark the official introduction of UNITY VCS (Vitreoretinal Cataract System) and UNITY CS (Cataract System), Alcon's next-generation Phaco/Vit platform, to the Indian market. Alcon IOL Symposium - Stay Ahead with the Clareon® Collection on Friday, 22 August 2025,12:30pm to 13:25pm IST at Convention Hall 2, Ground Floor. This session will cover the Clareon Collection as a comprehensive IOL portfolio, discuss optical differentiation and performance of newer EDOF IOLs, and highlight the role of digital image guidance in toric correction. Alcon Surgical Video Symposium - Experience Extraordinary Phaco & VR Surgery with the NEW UNITY® VCS by Alcon on Saturday, 23 August 2025, 12:00pm to 12:55pm IST at Convention Hall 2, Ground Floor. Through live discussion and videos, leading surgeons will showcase their experience with UNITY VCS in cataract and vitreoretinal procedures. Alcon Global Medical Affairs symposium - Vivity IOL, A True EDOF IOL with Proven Real-World Performance on Saturday, 23 August 2025, 13:00pm to 14:00pm IST at Seminar Hall 2, Ground Floor. The session, moderated by Dr. Vaishali Vasavada, will review meaningful real-world evidence supporting the use of Vivity IOL in special populations. To reserve your seat, visit For information on Alcon's presence at APACRS 2025, including the symposia and exhibition taking place at booth #A1, please visit the company's event page. The site will be updated following the event with on-demand content, such as archives of the symposia. Join the conversation on social platforms with the hashtag #APACRS2025 #Alcon. About the AcrySof IQ Vivity IOL The Wavefront Shaping AcrySof® IQ Vivity Extended Vision Posterior Chamber Intraocular Lens Model DFT015 (referred to as AcrySof IQ Vivity IOL) is a UV-absorbing and blue light-filtering foldable intraocular lens (IOL). This IOL, compared to a monofocal IOL, provides an extended range of vision from distance to near without increasing the incidence of visual disturbances.1 About UNITY VCS and UNITY CS The UNITY VCS (Vitreoretinal Cataract System) console, when used with compatible devices, is indicated for use during anterior segment (i.e. phacoemulsification and removal of cataracts) and posterior segment (i.e. vitreoretinal) ophthalmic surgery. In addition, with the optional laser this system is indicated for photocoagulation (i.e. vitreoretinal and macular pathologies), iridotomy and trabeculoplasty procedures. The UNITY CS (Cataract System) console, when used with compatible devices, is indicated for use during anterior segment (i.e. phacoemulsification and removal of cataracts) ophthalmic surgery.2 About Alcon Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people's lives. Our Surgical and Vision Care products touch the lives of people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at The content of this press release is intended for use by healthcare professionals only, including Registered Medical Practitioners, hospitals, or laboratories, and its use in any publication is subject to applicable local laws and regulations. References Acrysof IQ Vivity Extended Vision IOL Global Directions for Use [REF-22568] UNITY VCS and CS User Manual 2024 [REF-27652] Connect with us on: Facebook LinkedIn View source version on Contacts Media Relations MinSeo +821063849533 Pooja 9884646793


Business Insider
25 minutes ago
- Business Insider
Nvidia's (NVDA) Market Cap Now Eclipses the Entire Russell 2000 Index
Nvidia (NVDA) has seen its market value balloon to a staggering $4.4 trillion, which puts the semiconductor giant well ahead of nearly every other public company. To understand just how massive that is, consider that Nvidia is worth about $1.4 trillion more than the combined market capitalization of all 2,000 companies in the Russell 2000 index (IWM). This not only highlights Nvidia's incredible scale but also the growing gap between tech mega-caps and the broader small-cap market. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. What makes Nvidia's rise even more significant is just how important it has become to global investment portfolios. In fact, the company is currently included in 667 different exchange-traded funds (ETFs) that use both passive index and actively managed strategies. As a result, these ETFs collectively own approximately 3.6 billion shares of Nvidia, thereby making it one of the most widely held stocks in the world. This level of exposure is due to Nvidia's critical role in exciting technologies like artificial intelligence, data centers, and high-performance computing, which has led to a high level of investor confidence. However, it is worth noting that competition is heating up, and Nvidia will need to continue investing heavily in research and development in order to stay ahead. Otherwise, its massive size could end up creating a massive drag on all the portfolios that hold its shares. What Is a Good Price for NVDA? Turning to Wall Street, analysts have a Strong Buy consensus rating on NVDA stock based on 35 Buys, two Holds, and one Sell assigned in the past three months, as indicated by the graphic below. Furthermore, the average NVDA price target of $191.26 per share implies 5.5% upside potential.
Yahoo
30 minutes ago
- Yahoo
CytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program
SINGAPORE, Aug. 18, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ('CytoMed' or 'Company'), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor blood-derived, cell-based allogeneic therapies for the affordable treatment of blood and solid cancers, is pleased to announce that it entered into an At-the-Market Sales Agreement (the 'Sales Agreement') with R.F. Lafferty & Co., Inc. (the 'Agent'), as the sales agent. Pursuant to the Sales Agreement, the Company may offer and sell through the Agent, ordinary shares, no par value (the 'Shares'), of the Company having an aggregate value of up to U.S.$4,304,945. The timing and amount of any sales of Shares under the ATM program will be determined by the Company at its discretion, depending on market conditions and the Company's capital requirements. The Company intends to use the proceeds from the ATM program for general corporate purposes, which may include business diversification and development initiatives and capital expenditures. We may also use a portion of the net proceeds from this offering to appoint professionals to explore potential acquisitions or strategic investments in complementary businesses or technologies. However as of the date of this press release, the Company has not entered into any definitive agreements. The Company will provide updates to shareholders as additional information becomes available. In the event that any net proceeds are not immediately applied, we may temporarily hold them as cash or deposit them in banks. For information, the Company's newly acquired cord blood bank has seen approximately 2,500 new customer sign-ups since acquiring it in August 2024, contributing to revenue in 2025. About CytoMed Therapeutics Limited (CytoMed) Incorporated in 2018, CytoMed was spun off from the Agency for Science, Technology and Research (A*STAR), Singapore's leading research and development agency in the public sector. CytoMed is a clinical stage biopharmaceutical company focused on harnessing its licensed proprietary technologies, namely gamma delta T cell and iPSC-derived gamma delta Natural Killer T cell, to create novel cell-based allogeneic immunotherapies for the treatment of various human cancers. The development of novel technologies has been inspired by the clinical success of existing CAR-T therapies in treating haematological malignancies, as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumours. For more information, please visit and follow us on Twitter ('X') @CytomedSG, on LinkedIn, and Facebook. Forward-Looking Statements This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as 'may, 'will, 'intend,' 'should,' 'believe,' 'expect,' 'anticipate,' 'project,' 'estimate' or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company's plans to develop and commercialize its product candidates; the initiation, timing, progress and results of the Company's current and future pre-clinical studies and clinical trials and the Company's R&D programs; the Company's estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company's ability to successfully acquire or obtain licenses for additional product candidates on reasonable terms; the Company's ability to establish and maintain collaborations and/or obtain additional funding and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at The Company undertakes no obligation to publicly revise these forward–looking statements to reflect events or circumstances that arise after the date hereof. Contact : CytoMed Therapeutics Limitedenquiry@ : Evelyn Tan, Chief Corporate Officer